Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and pharmacokinetics of MK-6916 in healthy Japanese participants
jRCT2051250190Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of MK-6916 in pain (7 arms), sponsored by Merck & Co. Primary endpoints: Adverse events and Discontinuation due to adverse events. Started Feb 2026; status: recruiting.
02
Drugs
MK-6916
03
Conditions
pain
Beyond the preview
Go deeper on jRCT2051250190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250190.